Pathology and Stem Cell Research Center, Department of Pathology, School of Medicine, Kerman University of Medical Sciences, Kerman, Iran.
Department of General Surgery, School of Medicine, Kerman University of Medical Sciences, Kerman, Iran.
J Cardiothorac Surg. 2024 Sep 3;19(1):510. doi: 10.1186/s13019-024-02983-6.
Myasthenia gravis is an autoimmune disease with high prevalence of thymus disorders, in which, thymectomy is considered one of the therapeutic approaches in improving the patients' clinical outcomes. Today, thoracoscopic thymectomy has received significant attention than the classic transsternal approach due to fewer complication. Therefore, this study was designed with the aim of investigating the therapeutic outcomes of thymectomy in patients with myasthenia gravis in the Afzalipour Hospital of Kerman between 2011 and 2021.
The current study is a descriptive analytical study on patients with myasthenia gravis who underwent surgical thymectomy within 2011-2021. Demographic and clinical characteristics of patients from the time of operation to three years of follow-up were extracted and recorded from clinical records or by phone calls. Data were analyzed using SPSS software.
The data of 70 patients who underwent surgical thymectomy were analyzed. Thymectomy caused a significant reduction in the severity of the disease according to the Osserman classification (P = 0.001). It also significantly reduced the use of corticosteroids (P = 0.001) and IVIG (P = 0.015) compared to the time before the surgery. Sixty-two patients (88.57%) needed to take less medicine than before surgery. Left VATS was associated with less post-operative severity of the disease (P = 0.023). There were only two deaths during the follow-up period.
Overall, the findings of the present study demonstrated that thoracoscopic thymectomy is a useful surgical approach that leads to faster recovery, reducing the severity of the disease, need for medication, and complications in patients with myasthenia gravis, In comparison with the transsternal approach.
重症肌无力是一种自身免疫性疾病，胸腺疾病的患病率较高，其中胸腺切除术被认为是改善患者临床结果的治疗方法之一。如今，由于并发症较少，胸腔镜胸腺切除术比经典的胸骨切开术更受关注。因此，本研究旨在调查 2011 年至 2021 年期间克尔曼阿法利普尔医院接受胸腺切除术的重症肌无力患者的治疗结果。
本研究是一项对 2011 年至 2021 年期间接受手术胸腺切除术的重症肌无力患者的描述性分析研究。从手术时间到 3 年随访期，从临床记录或电话中提取并记录患者的人口统计学和临床特征。使用 SPSS 软件分析数据。
分析了 70 例接受手术胸腺切除术的患者的数据。根据 Osserman 分类，胸腺切除术显著降低了疾病严重程度（P=0.001）。与手术前相比，它还显著降低了皮质类固醇（P=0.001）和 IVIG（P=0.015）的使用量。62 例患者（88.57%）需要服用的药物少于手术前。左胸腔镜与术后疾病严重程度较轻相关（P=0.023）。随访期间只有 2 例死亡。
总体而言，本研究的结果表明，胸腔镜胸腺切除术是一种有用的手术方法，可使重症肌无力患者更快康复，降低疾病严重程度、药物需求和并发症的发生率，与胸骨切开术相比。
